טסיגנה 150 מג
novartis israel ltd - nilotinib as hydrochloride monohydrate - קפסולות - nilotinib as hydrochloride monohydrate 150 mg - nilotinib - nilotinib - treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.
טפמטקו
merck serono ltd - tepotinib as hydrochloride hydrate - טבליות מצופות פילם - tepotinib as hydrochloride hydrate 225 mg - tepotinib
טסיגנה 200 מג
novartis israel ltd - nilotinib as monohydrate - קפסולות - nilotinib as monohydrate 200 mg - nilotinib - nilotinib - treatment of philadelphia chromosome positive chronic myeloid leukaemia (ph+ cml) in chronic or accelerated phase in patients resistant to or experiencing significant toxicity during treatment with imatinib.treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.
ווטריינט 200 מג
novartis israel ltd - pazopanib as hydrochloride - טבליות מצופות פילם - pazopanib as hydrochloride 200 mg - pazopanib - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
ווטריינט 400 מג
novartis israel ltd - pazopanib as hydrochloride - טבליות מצופות פילם - pazopanib as hydrochloride 400 mg - pazopanib - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
ווטריינט 200 מ"ג
glaxo smith kline (israel) ltd - pazopanib as hydrochloride 200 mg - film coated tablets - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
ווטריינט 400 מ"ג
glaxo smith kline (israel) ltd - pazopanib as hydrochloride 400 mg - film coated tablets - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
בוסוליף 100 מג
pfizer pharmaceuticals israel ltd - bosutinib as monohydrate - טבליות מצופות פילם - bosutinib as monohydrate 100 mg - bosutinib
בוסוליף 500 מג
pfizer pharmaceuticals israel ltd - bosutinib as monohydrate - טבליות מצופות פילם - bosutinib as monohydrate 500 mg - bosutinib
בוסוליף 400 מג
pfizer pharmaceuticals israel ltd - bosutinib as monohydrate - טבליות מצופות פילם - bosutinib as monohydrate 400 mg - bosutinib